Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignaty Leshchiner

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2022
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast CancerJunko Tsuji, Tianyu Li, Albert Grinshpun, et al.
NPJ Precision Oncology|June 7, 2018
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimensPriscilla K Brastianos, Naema Nayyar, Daniel Rosebrock, et al.
Cancer Discovery|June 11, 2021
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease HistoryLivius Penter, Satyen H Gohil, Caleb Lareau, et al.
Blood Cancer Discovery|September 5, 2024
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA MutationsLivius Penter, Nicoletta Cieri, Katie Maurer, et al.
Cancer Discovery|August 18, 2021
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast CancerJames T Coates, Sheng Sun, Ignaty Leshchiner, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Cell Reports|September 8, 2021
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.
Nature Cell Biology|November 9, 2021
The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 functionKatarzyna Koltowska, Kazuhide S Okuda, Marleen Gloger, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Blood Advances|October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Filippo Utro, Qing Wang, et al.
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2022
Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast CancerJunko Tsuji, Tianyu Li, Albert Grinshpun, et al.
NPJ Precision Oncology|June 7, 2018
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimensPriscilla K Brastianos, Naema Nayyar, Daniel Rosebrock, et al.
Cancer Discovery|June 11, 2021
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease HistoryLivius Penter, Satyen H Gohil, Caleb Lareau, et al.
Blood Cancer Discovery|September 5, 2024
Tracking Rare Single Donor and Recipient Immune and Leukemia Cells after Allogeneic Hematopoietic Cell Transplantation Using Mitochondrial DNA MutationsLivius Penter, Nicoletta Cieri, Katie Maurer, et al.
Cancer Discovery|August 18, 2021
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast CancerJames T Coates, Sheng Sun, Ignaty Leshchiner, et al.
Nature Communications|December 21, 2017
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapyDan A Landau, Clare Sun, Daniel Rosebrock, et al.
Cell Reports|September 8, 2021
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.
Nature Cell Biology|November 9, 2021
The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 functionKatarzyna Koltowska, Kazuhide S Okuda, Marleen Gloger, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Blood Advances|October 26, 2022
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Filippo Utro, Qing Wang, et al.
Pageof 7